Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06347562 Recruiting - Clinical trials for Neurodevelopmental Disorder (Diagnosis)

Optical Genome Mapping for the Diagnosis of Neurodevelopmental Disorders

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

to evaluate the ability of the Optical genome Mapping (OGM) approach to detect simple and complex constitutional chromosomal aberrations of clinical relevance, which had previously been identified with standard diagnostic approaches (karyotyping, FISH, CNV-microarray) in the context of neurodevelopmental disorders (NDDs) with/wo congenital anomalies (CA)

NCT ID: NCT06341387 Recruiting - Lung Cancer Clinical Trials

Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer

Start date: May 5, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this prospective, case-control study is to discover the specific "omics" biomarkers of early stage of lung cancer using the non-invasive samples (breath, urine and serum) in a total of 200 subjects (100 healthy controls and 100 lung cancer patient). The main questions it aims to answer are: - Which are the "omics" biomarkers that characterize the early stage of lung cancer? - How to Translate Laboratory Data into Clinical Data? For each participant we will collected the breath, urine and blood samples. In lung cancer patients group the samples will be sample before lung cancer resection. The samples of Breath, urine and serum will be analysed using different type of analysis: eNose and the Gas Chromatography combined with Ion Mass Spectrometry (GC/IMS). Moreover, Serum will be analyzed by mass-spectrometry-based proteomics. The purpose of these analyses will be to find biomarkers capable of distinguishing the early-stage of lung cancer from the healthy group. Followup will be performed to evaluate the possible change of the volatolomic and proteomic profile.

NCT ID: NCT06328712 Recruiting - Clinical trials for Charcot-Marie-Tooth Disease Type 1A

Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A

Start date: March 2024
Phase: Phase 1
Study type: Interventional

An Open, Dose-escalation, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients with Charcot-Marie-Tooth Disease type 1A (CMT1A)

NCT ID: NCT06315114 Recruiting - Mental Disorder Clinical Trials

A Transdiagnostic Mentalization-based Intervention for Parents With Mental Disorders

LIGHTHOUSE
Start date: March 11, 2024
Phase: N/A
Study type: Interventional

The aim of this randomised clinical trial is to evaluate the short and longterm effects of a transdiagnostic mentalization-based intervention (Lighthouse MBT Parenting Program) compared to care as usal (CAU) for parents with a mental disorder in adult mental health service.

NCT ID: NCT06291779 Recruiting - Pancreas Cancer Clinical Trials

Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine

Start date: November 30, 2022
Phase:
Study type: Observational [Patient Registry]

- This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. - It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.

NCT ID: NCT06286267 Recruiting - Clinical trials for Artificial Intelligence

AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors

Start date: March 1, 2023
Phase:
Study type: Observational

Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border, stromal cellularity, stromal atypia, mitotic activity and stromal overgrowth. Malignant PTs account for 18%-25%, with high local recurrence (up to 65%) and distant metastasis rates (16%-25%). Benign PT could progress to malignancy after multiple recurrences. Therefore, Early, accurate diagnosis and identification of therapeutic targets are crucial for improving outcomes and survival rates. In recent years, there has been growing interest in the application of artificial intelligence (AI) in medical diagnostics. AI can integrate clinical information, histopathological images, and multi-omics data to assist in pathological and clinical diagnosis, prognosis prediction, and molecular profiling.AI has shown promising results in various areas, including the diagnosis of different cancers such as colorectal cancer, breast cancer, and prostate cancer. However, PT differs from breast cancer in diagnosis and treatment approach. Therefore, establishing an AI-based system for the precise diagnosis and prognosis assessment of PT is crucial for personalized medicine. The research team, led by Dr. Nie Yan, is one of the few in Guangdong Province and even nationally, specializing in PT research. Their team has been conducting research on the malignant progression, metastasis mechanisms, and molecular markers for PT. The team has identified key mechanisms, such as fibroblast-to-myofibroblast differentiation, and the role of tumor-associated macrophages in promoting this differentiation. They have also identified molecular markers, including miR-21, α-SMA, CCL18, and CCL5, which are more accurate in predicting tumor recurrence risk compared to traditional histopathological grading. The project has collected high-quality data from nearly a thousand breast PT patients, including imaging, histopathology, and survival data, and has performed transcriptome gene sequencing on tissue samples. They aim to build a comprehensive multi-omics database for breast PT and create an AI-based model for early diagnosis and prognosis prediction. This research has the potential to improve the diagnosis and treatment of breast PT, address the disparities in breast PT care across different regions in China, and contribute to the development of new therapeutic targets.

NCT ID: NCT06222346 Recruiting - Clinical trials for Subthreshold Depression

Online Peer Support in Long-term Conditions

Start date: February 2024
Phase: N/A
Study type: Interventional

Over 15 million people in England live with a long-term physical health condition. Low mood, loneliness and worry related to chronic illness are very common. In partnership with people with long-term conditions we have co-designed an online peer support platform to help people with health problems connect, support others, share experiences, and receive evidence-based information and advice on self-management. This study explores if the platform is feasible to implement and acceptable for people with long-term conditions experiencing mild depressive symptoms. Those allocated to the intervention arm will be invited to try out an online peer support platform with psychoeducational resources named "CommonGround". Those in the control arm will be guided to use the National Health Service NHS "Mental Health" webpages.

NCT ID: NCT06213220 Recruiting - Mood Disorders Clinical Trials

Wearable Devices System Diagnoses Mood Disorder in Children and Adolescents

Start date: January 3, 2023
Phase:
Study type: Observational

As a diagnostic test, this study aims to explore the effectiveness of systems based on wearable devices in identifying mood disorders in children and adolescents.

NCT ID: NCT06162338 Recruiting - Clinical trials for Gaucher Disease Type I

A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I

LY-M001
Start date: October 30, 2023
Phase: N/A
Study type: Interventional

This is a prospective single-center, open, single-arm, single-dose intravenous infusion study to evaluate the safety and initial efficacy, pharmacodynamic characteristics, immunogenicity, biodistribution, and viral shedding of LY-M001 injection.This study mainly includes the main study stage and the long-term follow-up study stage.

NCT ID: NCT06143995 Recruiting - Clinical trials for Cardiovascular Diseases

The Diagnosis and Treatment Pattern of CKD in Patients With Cardiovascular Disease- a National Cross-sectional Study

CREATIVE
Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about in a total of approximately 2000 patients with cardiovascular disease recruited from about 25 participating sites in China with eGFR<60 ml/min/1.73 m2 and/or UACR>30 mg/g at least twice 3 months apart within the previous 12 months who had been hospitalized in the cardiology department within the previous 12 months. The main questions it aims to answer are: - To estimate the diagnosis rate of CKD in patients with cardiovascular disease and laboratory evidence of CKD - To describe the CKD awareness and treatment pattern in patients with cardiovascular disease and laboratory evidence of CKD. - To describe the socio-demographic and clinical characteristics of CKD in patients with cardiovascular disease and laboratory evidence of CKD Participants will be invited to undergo a baseline visit, and the demographics, lifestyle factors, clinical characteristics, and laboratory tests will be collected.